MaxCyte
MaxCyte is the global leader in electroporation technology, the pre-eminent technology supporting non-viral cell and gene therapies, such as gene editing therapies
Investment Facts
MaxCyte
MaxCyte is the global leader in electroporation technology, the pre-eminent technology supporting non-viral cell and gene therapies, such as gene editing therapies
Key facts
- Sales $26m
- Employees c.65
- Industry Life Sciences & Healthcare
- Headquarters North America
- Geographic Footprint Europe, North America
- Website www.maxcyte.com
- Investment Date February 2021
- Fund VIP III Cortex
- Electroporation technology to pharma and biotech for cell therapy development as well as for drug discovery
- Electroporation is a leading non-viral method of introducing genetic material to a cell
- Attractive and highly scalable business model of licensing the technology and devices for an annual fee, repeat consumables, development milestone payments and royalties on end-market sales of any products using their tech